CDR-813 demonstrates high target-specific binding and antitumor potency in preclinical models
Sep. 20, 2024
CDR-Life Inc. has reported preclinical data for the CDR-813, a novel antibody fragment-based bivalent T-cell engager targeting preferentially expressed antigen in melanoma (PRAME) on HLA-A*02:01.
